Zenas BioPharma, Inc. (ZBIO) Stock Forecast
ZBIO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 8 analysts
- Price target
- $47.88 average of analyst targets
- Upside to target
- +92.7% from the latest close
- Next earnings
- —
- 52-week range
- $15.20 – $43.17
ZBIO analyst ratings
8 analystsNumber of analysts at each rating.
ZBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ZBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.27 | −$1.31 | −$1.23 | −$1.22 | −4.1% | 2 |
| Current fiscal year (2026) | −$5.62 | −$5.83 | −$5.40 | −$4.83 | −16.2% | 2 |
| Next fiscal year (2027) | −$4.66 | −$5.11 | −$4.21 | −$5.62 | +17.0% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ZBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $12.3M | $1.0M | $57.3M | +22.6% | 5 |
| Next fiscal year (2027) | $57.9M | $27.6M | $94.7M | +372.5% | 6 |
ZBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ZBIO revenue: reported and forecast
ZBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.31 | −$1.31 | −$1.31 | −$1.31 | −$1.27 | −3.1% | 1 up · 1 down |
| Current fiscal year (2026) | −$4.33 | −$4.33 | −$4.29 | −$4.29 | −$5.62 | +29.6% | 0 up · 2 down |
| Next fiscal year (2027) | −$2.27 | −$2.27 | −$2.27 | −$2.27 | −$4.66 | +105.7% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ZBIO earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; ZBIO beat in 3 of 9.
What analysts expect from ZBIO
8 analysts cover Zenas BioPharma; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $47.88, 92.7% above the latest close of $24.84. Analysts expect earnings of −$5.62 per share for 2026, −16.2% from a year earlier. For 2027 the average estimate is −$4.66 per share on revenue of $57.9 million. Zenas BioPharma beat the EPS estimate in 3 of the last 9 quarters.
Related: ZBIO income statement, ZBIO key metrics, ZBIO chart. See the ZBIO stock overview for the latest quote and news.
ZBIO forecast FAQ
What is Zenas BioPharma's price target?
The average analyst price target for Zenas BioPharma is $47.88, 92.7% above the latest close of $24.84.
Is Zenas BioPharma a buy, hold or sell?
Of 8 analysts covering Zenas BioPharma, 7 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Zenas BioPharma's EPS forecast?
Analysts forecast −$5.62 per share for 2026 (range −$5.83 to −$5.40); for 2027 the estimate is −$4.66.
What is Zenas BioPharma's revenue forecast?
The average revenue estimate for 2026 is $12.3 million, growth of 22.6%; for 2027 it is $57.9 million.
Does Zenas BioPharma usually beat earnings estimates?
Zenas BioPharma reported EPS at or above the analyst estimate in 3 of the last 9 quarters.